Eli Lilly rated SELL: rich valuation priced for perfection, rising GLP-1 competition, pricing pressure, and patent-cliff risk. Click here to read more on LLY stock.
Local columnist Len Calderone laments the social and emotional costs of replacing human interaction with cold, confusing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results